Health

Training of the manpower involved in the program have been conducted virtually using platforms like National Information Center (NIC), ECHO, Integrated Government Online training’ (iGOT) portal on digital infrastructure for knowledge sharing (DIKSHA) platform of Ministry of Human Resource Development (MHRD), educational satellite (EDUSAT) (in use in Madhya Pradesh), or other available online training platforms. Developmental partners have supported the state and districts in organizing trainings using virtual platforms.

In a boon to aneurysm patients at the risk of stroke in the brain, Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST),Thiruvananthapuram, and National Aerospace Laboratories of CSIR (CSIR-NAL) have developed an indigenous flow diverter stent that is easily affordable than the imported ones.

In a significant development, Bharat Biotech has sought Drug Controller General India’s (DCGI) approval to conduct nasal COVID-19 vaccine trials in India. The company has developed a new single-dose nasal COVID-19 vaccine in a partnership with Washington University in St Louis, USA. There are no intra-nasal COVID-19 vaccines under trial in India at the moment.

Indians will soon have access to the country’s first indigenous flow diverter stent for diverting blood flow away from localized ballooning of arteries in the brain and a device that promotes better healing of the hole in the heart.

Describing the exercise as the start of the climax of the pandemic that started a year before, Dr. Harsh Vardhan said, “The Prime Minister Shri Narendra Modi has been personally involved in the management of the pandemic since the start. Today marks the culmination of five months’ hard work on rolling out the COVID vaccines.”

“mRNA-based vaccines are scientifically the ideal choice to address a pandemic because of their rapid developmental timeline. They are highly efficacious because of their inherent capability of being translatable into the protein structure inside the cell cytoplasm. Additionally, mRNA vaccines are fully synthetic and do not require a host for growth, e.g. eggs or bacteria,” said a release issued b DBT on December 11.

India successfully cultures the new viral strain on the horizon (UK-variant of SARS-CoV-2), the Indian Council of Medical Research (ICMR) said, on Saturday.

About 201 acres of land has been allotted for the project, according to a release issued by the Prime Minister’s Office. It will be built at an estimated cost of Rs1,195 crore, and is expected to be completed by mid-2022.